Langbahn Team – Weltmeisterschaft

MINE (chemotherapy)

MINE in the context of chemotherapy is an acronym for one of the chemotherapy regimens used for treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.

Today this regimen is often combined with monoclonal antibody rituximab. In this case the regimen is called R-MINE or MINE-R.[citation needed]

The [R]-MINE regimen consists of:

  1. Rituximab - anti-CD20 monoclonal antibody that can kill both normal CD20-expressing B cells and malignant ones;
  2. Mesna to prevent the development of hemorrhagic cystitis which may otherwise result from ifosfamide administration;
  3. Ifosfamide - an alkylating antineoplastic agent from oxazafosforine group;
  4. Mitoxantrone - a synthetic anthracycline analogue (anthraquinone) that is able to intercalate DNA and thus prevent cell division (mitosis);
  5. Etoposide - a topoisomerase inhibitor.[1][2]

Dosing regimen

Drug Dose Mode Days
Rituximab 375 mg/m2 IV infusion Day 1
Mesna 1330 mg/m2 IV infusion over 1h together with ifosfamide, plus 500 mg PO 4h after ifosfamide Days 1-3
Ifosfamide 1330 mg/m2 IV infusion over 1h Days 1-3
Mitoxantrone 8 mg/m2 IV infusion Day 1
Etoposide 65 mg/m2 IV infusion over 1h Days 1-3

References

  1. ^ A phase II trial of mesna / ifosfamide, mitoxantrone and etoposide for refractory lymphomas
  2. ^ Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Quelle: https://en.wikipedia.org/wiki/MINE-R